Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
AHA 2026
Outcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial of FXIA Inhibition with asundexian in participants with non-cardioembolics stroke of transient ischemic attack by non-laboratory Framingham Risk Score Category
In patients with recent NCIS or high-risk TIA, asundexian reduced ischemic stroke with similar bleeding versus placebo across all FRS risk categories
- There was no significant interaction between treatment and FRS risk categories for efficacy and safety outcomes
- There was no evidence that the effect of asundexian differs by baseline vascular risk .
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
